Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Local growth hormone promotes benign prostatic hyperplasia
Masaki Ryuzaki, Svetlana Zonis, Neil A. Bhowmick, Sandrine Billet, Saravana Kumar Kailasam Mani, Stephen J. Freedland, Hyung L. Kim, Vera Chesnokova, Shlomo Melmed
Masaki Ryuzaki, Svetlana Zonis, Neil A. Bhowmick, Sandrine Billet, Saravana Kumar Kailasam Mani, Stephen J. Freedland, Hyung L. Kim, Vera Chesnokova, Shlomo Melmed
View: Text | PDF
Research Article Aging Endocrinology

Local growth hormone promotes benign prostatic hyperplasia

  • Text
  • PDF
Abstract

Locally produced nonpituitary growth hormone (npGH) promotes DNA damage accumulation and epithelial-mesenchymal transition (EMT) in aging human colon epithelium. GH receptor (GHR) and npGH are expressed in normal human prostate, and benign prostatic hyperplasia (BPH) prevalence increases with age. We hypothesized that local prostate GH action may promote EMT and contribute to BPH pathogenesis. We show here that the number of patients expressing npGH increases more than 10-fold after age 60, concordant with increased γH2AX, a marker of DNA damage, and EMT activation. GH-treated human primary prostate epithelial cells, normal prostate cells, and primary cell cultures derived from resected BPH specimens exhibited enhanced DNA damage and activated EMT, with induced TWIST2, suppressed E-cadherin, and increased Ki67, cell motility, and proliferation. In mice, prostate tissue adjacent to allografted GH-expressing fibroblasts showed increased γH2AX, TWIST2, and Ki67, along with morphological changes consistent with BPH. While GH and GH-induced IGF-1 both activated EMT, GH triggered DNA damage independently of IGF-1. These results elucidate what we believe to be a novel role for local npGH in aging prostate tissue, whereby npGH increases DNA damage and promotes EMT to enable a microenvironment favoring BPH development. Prostate GHR signaling may be an attractive therapeutic target for BPH.

Authors

Masaki Ryuzaki, Svetlana Zonis, Neil A. Bhowmick, Sandrine Billet, Saravana Kumar Kailasam Mani, Stephen J. Freedland, Hyung L. Kim, Vera Chesnokova, Shlomo Melmed

×

Figure 3

Age-associated stimulation of prostate EMT and proliferation are mediated by npGH.

Options: View larger image (or click on image) Download as PowerPoint
Age-associated stimulation of prostate EMT and proliferation are mediate...
(A–F) Human prostate TWIST1/2 expression increases with age. Representative IHC images of TWIST1/2 expression (brown) in normal human prostate tissue specimens derived from patients aged (A and B) 30, (C and D) 45, and (E and F) 80 years. Magnification is ×10 in A, C, and E, and ×20 in insets in B, D, and F. Scale bars: 100 μm. (G) Graph depicts percentage of samples positive for TWIST1/2 in normal human prostate tissue. IHC scores of ≥70 were considered positive. Each dot represents an individual patient with positive TWIST1/2. **P < 0.01 by χ2 test, as shown in Supplemental Figure 3A. (H–J) Endocrine GH induces prostate cell EMT and proliferation. Western blot of EMT markers in (H) HPrEC line 1, (I) HPrEC line 2, and (J) PNT2. Cells were treated with indicated GH doses and analyzed 24 hours later. Representative blots from at least 2–4 independent experiments are shown. ImageJ quantification of Western blots is depicted in Supplemental Figure 3, C–E. For H, the Western blot membrane from Figure 2D was stripped and re-probed for TWIST2 and Ki67; the GAPDH loading control is the same. (K–M) Migration of (K) HPrEC line 1, (L) HPrEC line 2, and (M) PNT2 cells treated with GH. Cells were plated into migration chambers with GH (100 ng/mL) or left untreated (control); 24 hours later, cells were stained with crystal violet, imaged (magnification, ×100), and the number of migrated cells was assessed. Results shown are mean ± SEM. Each dot represents results of 3 separate experiments performed in duplicate. Results are shown as percentage of control, but statistical testing was performed on raw numbers. Results in K–M were analyzed by 2-tailed Student’s t test. **P < 0.01 versus control.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts